The combo of tislelizumab and chemotherapy produced sustained and clinically meaningful survival benefits with manageable toxicity among patients with recurrent or metastatic #nasopharyngealCancer. From @jamaoncology.com

Read more here: ➡️ https://bit.ly/4rTgs5h

#HeadandNeckCancer #HNSCC #MedOnc

Keytruda cleared for NHS use in early head and neck cancer MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer

#Keytruda #pembrolizumab #immunotherapy #headandneckcancer #PharmaNews #MSD #NICE #reimbursement #NICEfinaldraftguidance #NHSEngland #headandnecksquamouscellcarcinoma #HNSCC #LAHNSCC #PDL1biomarker #PD1inhibitor #KEYNOTE689trial #perioperativeimmunotherapy #PDL1positiveHNSCC
zurl.co/y2cQh

Newly approved head and neck cancer treatment improves care for first time in more than 20 years The National Institute for Health and Care Excellence (NICE) has recommended an immunotherapy to treat advanced head and neck cancer for use on the NHS in England. In final draft guidance, published o...

For the first time in more than 20 years, people with advanced head and neck cancer in England have a newly approved systemic option, after NICE backed an immunotherapy for routine NHS use. #HeadAndNeckCancer #Immunotherapy #TCSC
pharmaceutical-journal.com/article/news...

🎉 Congratulations to Marc Oliva Bernal & Gema Bruixola on winning the #ICHNO26 Best Paper & Best Poster Awards!

👉 https://bit.ly/4sXElt9

#HeadAndNeckCancer

📢 Final day at #ICHNO26!
Inspiring discussions, valuable insights, and strong connections in head and neck oncology—let’s carry this momentum forward to shape the future of patient care.
👉 Stay tuned for final highlights of the day.

In collaboration with @ESMO & @EHNS

#HeadAndNeckCancer

Day 2 at ICHNO26 - ESTRO - OncoDaily Day 2 at ICHNO26 - ESTRO / cancer, EHNS, ESMO, ESTRO, ICHNO26, OncoDaily, Oncology

ESTRO - Day 2 at ICHNO26

@myesmo.bsky.social

oncodaily.com/voices/estro...

#ICHNO26 #HeadAndNeckCancer #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

📢 Day 2 at #ICHNO26! Momentum continues as experts dive deeper into the latest advances in head and neck oncology, sharing insights and strengthening multidisciplinary collaboration.
👉 Stay tuned for more highlights from Day 2.

#ICHNO26 #HeadAndNeckCancer

📢 Day 1 at #ICHNO26!
Kicked off today with experts from around the world coming together to advance head & neck oncology.

👉 Inspiring days ahead — stay tuned for highlights.

In collaboration with @myESMO & @EHNSociety

#HeadAndNeckCancer #Oncology

Register and Submit your Abstract to the "6th International Symposium on HPV-Infection in Head and Neck Cancer"
More info: www.ehns.org/site/newslet...
Registration & Abstract Submission: www.ukl-live.de/hpv-leipzig/...
#HPVinfection #HeadAndNeckCancer #HeadAndNeckOncology

Head & Neck Cancer Support Network Trust Community News March 2026 — Head and Neck Cancer Support Network Read our latest news for March, 2026.

3/3 If you or someone you love is affected by head & neck cancer, our community is here for you.

Read the full update 👇
www.headandneck.org.nz/hnc-news/feb...

#HeadAndNeckCancer #CancerSupport #Aotearoa #headnecknz

🚀Recently published 🚀

The stage of laryngeal cancer before and after the COVID-19 pandemic: A retrospective study

🔗Read the article: advances.umw.edu.pl/en/ahead-of-...

#academicpublishing #medicalresearch #MedicalInnovation #OpenScience #AdvClinExpMed
#LaryngealCancer #HeadAndNeckCancer

📢 New paper alert 📢

We used co-design with people living with incurable head & neck cancer, caregivers + HCPs to find the real “stress points” in their care (navigation + contacting teams came up a lot).

🔗 link.springer.com/article/10.1...

#HeadAndNeckCancer #CoDesign #cancerresearch #palliative

A #disulfidptosis-based model for #HeadAndNeckCancer predicts survival and links low-risk #tumors to stronger immunity, while #multiomics highlight CXCL12–CXCR4 and identify #NQO1, with #dicoumarol boosting checkpoint therapy.

#OpenAccess: doi.org/10.1016/j.ge...

Australian Scientists Develop Blood Test To Predict Head, Neck Cancer Relapse SYDNEY, Feb 25 (Bernama-Xinhua) — Scientists in Australia have developed a simple blood test that detects circulating tumour cells to pinpoint head and neck cancer patients at higher risk of relapse after surgery, reported Xinhua. Researchers analysed post-surgery blood samples and linked the presence of circulating tumour cells – cancer cells that have broken away from a tumour and entered the bloodstream – to increased recurrence odds, said a statement from Australia’s Centenary Institute on Wednesday. Around 5,500 Australians are diagnosed annually for head and neck cancer, which affects the lining of the mouth, throat and voice box. While many […]

Australian Scientists Develop Blood Test To Predict Head, Neck Cancer Relapse #CancerResearch #BloodTest #HeadAndNeckCancer #CancerSurvivor #HealthInnovation

🚨 Last chance to register for #ICHNO26 — late registration closes TODAY (25 Feb)!

📅 19–21 March 2026
📍 Seville, Spain
🤝 Joint ESTRO, ESMO & EHNS congress

Secure your spot 👉 bit.ly/3L2CHWn

#Oncology #HeadAndNeckCancer #Radonc

Enhorabuena a nuestra compañera Carmen Fernández-Cedrón Bermejo que ya es Doctora después de defender ayer su tésis“Molecular characterisation of external auditory canal squamous cell carcinomas” @sinonasalteam.bsky.social @HeadandNeckGroup @ORL_HUCA @Finbasturias #ISPA #headandneckcancer

The incidence of avid lesions in head and neck cancer patients undergoing positron emission tomography-computed tomography scanning | The Journal of Laryngology & Otology | Cambridge Core The incidence of avid lesions in head and neck cancer patients undergoing positron emission tomography-computed tomography scanning

New FirstView article: "The incidence of avid lesions in #HeadAndNeckCancer patients undergoing positron emission tomography-computed tomography scanning"
doi.org/10.1017/S002...

#PETCT #Oncology #Radiology #CancerResearch

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer

RYBREVANT FASPRO receives FDA Breakthrough Therapy Designation for advanced head and neck cancer, spotlighting urgently needed options for patients with limited choices.
#FDA #HeadAndNeckCancer #Oncology #CancerResearch #TCSC
www.jnj.com/media-center...

🔎 With this study, we hope to better understand the views of HNC survivors when it comes to difficulties, barriers, and factors involved on social isolation and loneliness during HNC treatment.

(3/3)

#CuthbertLab #HeadandNeckCancer #HNC

👤 Head and neck cancer treatment can come with burdens such as functional difficulties and social isolation, which negatively impact patients’ confidence, social integration, and overall quality of life.

(2/3)

#CuthbertLab #headandneckcancer #hnc

📣 Are you a head and neck cancer survivor interested in getting involved in research to help inform healthy policies and support the well-being of all cancer patients?

(1/3)

#CuthbertLab #headandneckcancer #hnc

🦙 Our new #review article is out now.💡
In "Ancient and Emerging Nanostructures for Innovations to Fight #HeadandNeckCancer" we highlight how diverse technologies are shaping the future for #HNSCC thearpy, also including our research focus about #Nanobodies🦙
Read more 👉 www.mdpi.com/2073-4409/15...

This review examines #MetabolicReprogramming in #HeadAndNeckCancer, detailing glucose, amino acid, and #LipidPathway changes plus immune alterations, and highlights metabolic targeting as a promising strategy for therapy development.
#OpenAccess: doi.org/10.1016/j.ge...

Synapse: Your Connection to our MSK Authors
Meet: Ian Ganly
Research Focus: Surgery; Attending

The use of protons in the management of recurrent, previously irradiated adenoid cystic carcinoma
synapse.mskcc.org/synapse/work...

#ProtonTherapy #AdenoidCysticCarcinoma #HeadAndNeckCancer

Dual PET approach for personalized head and neck cancer treatment Novel imaging strategy could push tumor control rates from 60% to over 90%

Beyond "one-size-fits-all": A new strategy that combines two types of #PET scans can guide personalized #radiotherapy for head and neck cancers, according to new research led by 🇸🇪 @stockholm-uni.bsky.social, published by @snm-mi.bsky.social. #HeadAndNeckCancer #PersonalizedMedicine

#WorldCancerDay En el equipo de @sinonasalteam.bsky.social eam seguimos trabajando cada día para mejorar diagnóstico y tratamiento de tumores raros de senos y fosas nasales @HeadNeckGroup @ORL-HUCA
@Finbasturias #ISPA #headandneckcancer #sinonasalcancer

Head and neck cancer kills 4000 people each year in the UK.
Remember to check yourself to give you and your loved ones peace of mind.
60 seconds. 3 steps. Once a month.
1. Touch
2. Open Wide
3. Speak
Do your check here: tinyurl.com/CMCA-Hanc
#headandneckcancer

📢 Abstract submissions are now open for #ICHNO26!
⏰ Late-breaking deadline: 11 Feb 2026

📅 19–21 March 2026 | 📍 Seville, Spain
🤝 Joint ESTRO, ESMO & EHNS congress

👉 Submit your abstract: bit.ly/3L2CHWn

#Oncology #HeadAndNeckCancer #CancerResearch

Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma - PharmaTimes More than 71% of patients treated with Unloxcyt achieved disease control

#oncology #generics #SunPharma #Unloxcyt #cosibelimab #CSCC #squamouscellcarcinoma #mCSCC #SCC #laCSCC #FDA #CK301101 #clinicaltrial #skincancer #headandneckcancer #checkpointinhibition #checkpointinhibitor

pharmatimes.com/news/sun-pha...

IMPT Delivers Superior OS, Less High-Grade Toxicity in Oropharyngeal Cancer - Oncology Nurse Advisor Intensity-modulated proton therapy (IMPT) improves overall survival (OS) and reduces high-grade toxicity compared with intensity-modulated radiation

IMPT improves OS and reduces high-grade toxicity compared with IMRT for adults with #oropharyngealCancer. Published in @thelancet.com and @cancertherapyadv.bsky.social.

https://bit.ly/4jBjWXm

#hncsm #headandneckcancer